Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Director/PDMR Shareholding

15 Dec 2008 09:33

RNS Number : 1234K
Hutchison China Meditech Limited
15 December 2008
 



 

Hutchison China MediTech Limited ("Chi-Med") 

(AIM: HCM)

Director's Shareholding

LondonMonday, 15 December 2008: Chi-Med was informed on 12 December 2008 that Mr Christian HoggExecutive Director and Chief Executive Officer of Chi-Med, purchased 100,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of 40p each on 12 December 2008.

Following this purchase, Mr Hogg is beneficially interested in 270,000 Shares, representing approximately 0.5% of the current issued share capital of Chi-Med. This is in addition to the 576,136 vested options held by him, representing approximately 1.1% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients. 

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGCBDDBXBGGIU
Date   Source Headline
23rd Aug 20217:00 amRNSHUTCHMED Selected for Certain Hang Seng Indexes
17th Aug 20219:30 amRNSELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
9th Aug 20217:00 amRNSHUTCHMED & Epizyme Announce TAZVERIK Collaboration
30th Jul 20219:30 amRNSTotal Voting Rights
28th Jul 202112:00 pmRNSInterim Results and Business Updates
28th Jul 20217:00 amRNSPhase II Trial of ORPATHYS Initiated
23rd Jul 202112:01 pmRNSStabilizing Actions & End of Stabilization Period
16th Jul 202110:50 amRNSHolding(s) in Company
16th Jul 20217:00 amRNSSurufatinib MAA Submitted and Validated by the EMA
14th Jul 20219:35 amRNSHolding(s) in Company
13th Jul 20217:00 amRNSFirst Commercial Sale of ORPATHYS® in China
12th Jul 20212:35 pmRNSFull Exercise of the Over-allotment Option
6th Jul 20219:30 amRNSHUTCHMED Initiates Phase I Trials of HMPL-295
2nd Jul 202111:15 amRNSHolding(s) in Company
2nd Jul 20219:30 amRNSNotice of Results
1st Jul 202111:00 amRNSUS FDA Accepts NDA Filing for Surufatinib
30th Jun 202110:02 amRNSHoldings in Company
30th Jun 202110:01 amRNSTotal Voting Rights
30th Jun 202110:00 amRNSClosing of Global Offering and Hong Kong Listing
29th Jun 20217:00 amRNSBlocklisting Six Monthly Return
23rd Jun 20213:21 pmRNSHUTCHMED Announces Pricing of Global Offering
22nd Jun 20216:22 pmRNSSavolitinib approved in China for lung cancer
18th Jun 20214:05 pmRNSHUTCHMED Announces NMPA Approval of Surufatinib
18th Jun 20217:01 amRNSHUTCHMED Launches Hong Kong IPO
18th Jun 20217:00 amRNSDisclosure Update
20th May 20217:00 amRNSClinical Data to be Presented at ASCO21
17th May 20217:00 amRNSHUTCHMED to Host Company Update
7th May 202112:00 pmRNSHUTCHMED to Attend Upcoming Investor Conferences
4th May 20218:00 amRNSChange of Company Name
4th May 20217:00 amRNSSurufatinib FDA Rolling NDA Submission Completed
30th Apr 20214:41 pmRNSSecond Price Monitoring Extn
30th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSPhase II Registration Study of HMPL-689 Initiated
28th Apr 20212:20 pmRNSResult of AGM
23rd Apr 20217:00 amRNSVesting of awards under Long Term Incentive Plan
14th Apr 202110:30 amRNSNotification of Dilution of Voting Rights
8th Apr 20218:30 amRNS$100m Investment by Baring Private Equity Asia
31st Mar 20217:00 amRNSTotal Voting Rights
29th Mar 20219:30 amRNSGrant of LTIP Awards and Share Options
29th Mar 20217:00 amRNSInitiates International Phase I Trials of HMPL-306
26th Mar 20217:00 amRNSAnnual Financial Report
24th Mar 20211:30 pmRNSAgreement to Divest Non-Core OTC Joint Venture
24th Mar 20217:00 amRNSPhase Ib/II Trial of Surufatinib with Tislelizumab
10th Mar 20217:00 amRNSVesting of awards under Long Term Incentive Plan
4th Mar 20213:15 pmRNSPublication of Form 20-F
4th Mar 202112:00 pmRNSFinal Results, Business Update and Name Change
3rd Feb 20217:00 amRNSNotice of Results
14th Jan 202110:00 amRNSSavolitinib Data to be Presented at Virtual WCLC
11th Jan 20217:00 amRNSChi-Med & Inmagene Announce Strategic Partnership
31st Dec 20207:00 amRNSBlocklisting Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.